Capricor Therapeutics
CAPR
About: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Employees: 160
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
5% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 38
10.05% less ownership
Funds ownership: 40.11% [Q1] → 30.06% (-10.05%) [Q2]
11% less funds holding
Funds holding: 120 [Q1] → 107 (-13) [Q2]
12% less call options, than puts
Call options by funds: $61.2M | Put options by funds: $69.8M
22% less capital invested
Capital invested by funds: $174M [Q1] → $136M (-$37.5M) [Q2]
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
HC Wainwright & Co.
Joseph Pantginis
|
$24
|
Buy
Reiterated
|
11 Sep 2025 |
|
Roth Capital
Boobalan Pachaiyappan
|
$12
|
Buy
Maintained
|
14 Jul 2025 |
|
B. Riley Securities
Madison El-Saadi
|
$21
|
Buy
Initiated
|
26 Jun 2025 |
|
Jones Trading
Catherine Novack
|
$29
|
Buy
Maintained
|
25 Jun 2025 |
|
Oppenheimer
Leland Gershell
|
$22
|
Outperform
Maintained
|
23 Jun 2025 |
Financial journalist opinion
Based on 92 articles about CAPR published over the past 30 days
